Sector: Pharmaceuticals & Biotechnology - Healthcare
BSE Code: 540702
NSE Symbol: LASA
ISIN: INE670X01014
📋 Lasa Supergenerics Confirms Non-Large Corporate Status Under SEBI Framework - Lasa Supergenerics Limited is not classified as a Large Corporate under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. - The company is exempt from the Large Entities framework requirements for deb…
Lasa Supergenerics Reports Q3 FY26 Results 📉: Net Loss of ₹255.47 Lakhs Amid Production Halt • Net loss of ₹255.47 lakhs in Q3 FY26, compared to a net profit of ₹549.39 lakhs in the same quarter last year. • Revenue from operations declined sharply to ₹219.93 lakhs from ₹3,307.99 lakhs year-over-…
📊 Lasa Supergenerics Q3 FY2026 Results Coming Soon • Board meeting scheduled for February 13, 2026 to review unaudited financial results for Q3 FY2026 (quarter ended December 31, 2025) • Trading window closed until 48 hours after results declaration
Lasa Supergenerics Appoints New Executive Director 🏢👨💼 - Mr. Ganesh Suresh Potdar appointed as Additional Director (Executive Director) & Occupier of all company units. - Term runs from January 02, 2026, to January 01, 2030. - Qualifications: Under Graduate. - Expertise: Business operations, b…
Lasa Supergenerics Welcomes New Company Secretary & Compliance Officer 🏛️ - Mrs. Mitti Jain appointed as Company Secretary & Compliance Officer at Lasa Supergenerics, effective December 16, 2025. - She is an Associate Member of ICSI and holds B.com and M.com degrees from the University of Gujarat…
Key Leadership Change at Lasa Supergenerics 🏢 - Mr. Prathmesh Chalke (DIN: 11119348) resigns as Whole-time Director of Lasa Supergenerics Limited. - Resignation effective from closing hours of Wednesday, 31st December 2025. - Resignation communicated via email dated 11th December 2025. - No other…
Lasa Supergenerics Ltd. Discloses Related Party Transactions for Q2 2025 📊 - Disclosed related party transactions for the quarter and half year ended September 30, 2025. - Includes transactions with Directors and Key Managerial Personnel. - Transaction types: Director's Remuneration, Sitting Fees…
Lasa Supergenerics Reports Q2 Losses Amid Fire Incident Impact 🔥📉 - Unaudited Q2 results show a net loss of ₹625.20 lakhs; H1 loss at ₹2,737.12 lakhs. - Revenue from operations dropped sharply to ₹306.11 lakhs for the quarter. - Fire on May 18, 2025, caused uninsured losses of ₹2,057.47 lakhs (i…
Lasa Supergenerics Q2 2025 Results: Fire Incident Impacts Financials 🔥📉 - Revenue for Q2 2025: ₹306.11 lakhs (vs. ₹3,939.49 lakhs in Q2 2024) - Total Income for Q2 2025: ₹306.81 lakhs (vs. ₹4,134.20 lakhs in Q2 2024) - Net Loss after tax: ₹625.20 lakhs (vs. ₹322.85 lakhs loss in Q2 2024) - May 2…
📅 Lasa Supergenerics Ltd: Q2 & H1 Financial Results Coming Soon - Board meeting scheduled for November 14, 2025. - Agenda includes approval of unaudited financial results for Q2 and H1 ending September 30, 2025. - Trading window closed until 48 hours post-results declaration. - Announcement avail…
📅 Lasa Supergenerics Ltd: Key Board Meeting & Financial Results Update - Board meeting scheduled for August 14, 2025. - Agenda includes approval of unaudited financial results for the quarter and half year ended September 30, 2025. - Trading window closed until 48 hours post-results declaration, …
Key Leadership Change at LASA Supergenerics 🏢 - Mrs. Mitti Jain resigned as Company Secretary & Compliance Officer of LASA Supergenerics Ltd. - Resignation effective from closing hours of August 29, 2025. - Reason cited: Company's non-operational status and absence of active business operations. …
Key Leadership Change at LASA Supergenerics Ltd 🏛️ - Mrs. Mitti Jain, Company Secretary & Compliance Officer of LASA Supergenerics Ltd, has resigned. - Resignation effective from August 29, 2025. - Reason cited: Company's current non-operational status and lack of active business operations. - Re…
Lasa Supergenerics Q1 FY26 Results: Revenue Drops, Net Loss Widens Amid Fire Incident 🔥📉 - Revenue from Operations for Q1 FY26: ₹2,001.18 lakhs (down from ₹3,083.55 lakhs in Q1 FY25) - Total Income for Q1 FY26: ₹2,014.60 lakhs (vs ₹3,084.02 lakhs in Q1 FY25) - Net Loss after tax for Q1 FY26: ₹2,…
Lasa Supergenerics Q1 2025 Results: Revenue Drops, Net Loss Widens Amid Fire Incident 🔥📉 - Revenue from Operations for Q1 2025: ₹2,001.18 lakhs (down from ₹3,083.55 lakhs in Q1 2024). - Total Income for Q1 2025: ₹2,014.60 lakhs (vs. ₹3,084.02 lakhs in Q1 2024). - Net Loss after tax for Q1 2025: …
📅 Lasa Supergenerics Ltd: Key Board Meeting & Financial Results Update - Board meeting scheduled for August 13, 2025 to approve unaudited financial results for the quarter ended June 30, 2025. - Trading window closed until 48 hours after financial results are declared. - Announcement available on…
🔍 Two Independent Directors Step Down from LASA Supergenerics Amid Non-Operational Status - Mr. Ajay Sukhwani and Ms. Ekta Gurnasinghani resigned as Independent Directors of LASA Supergenerics Limited, effective August 04, 2025. - Resignations were submitted via email, with the company's non-oper…
📉 Independent Director Resigns from LASA Supergenerics - Ms. Manali Bhagtani (DIN: 08067867) resigned as Independent Director of LASA Supergenerics Limited, effective July 31, 2025. - The resignation is due to the company's non-operational status and lack of business activity. - Ms. Bhagtani hold…
📋 Board Update: Independent Director Resigns from LASA Supergenerics • Mr. Hardesh Tolani (DIN: 07811319) resigned as Independent Director effective July 31, 2025 • Resignation due to company's non-operational status and lack of business activity • No other material reasons provided for resignati…
📉 LASA Supergenerics Director Resigns Citing Company's Non-Operational Status • Ms. Manali Bhagtani (DIN: 08067867) has resigned as Independent Director of LASA Supergenerics Limited, effective July 31, 2025. • The resignation is due to the company's non-operational status and lack of business ac…